blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3429628

EP3429628 - OLIGOLACTIC ACID CONJUGATES AND MICELLES WITH ENHANCED ANTICANCER EFFICACY [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  26.02.2021
Database last updated on 30.03.2026
FormerThe patent has been granted
Status updated on  20.03.2020
FormerGrant of patent is intended
Status updated on  30.10.2019
FormerRequest for examination was made
Status updated on  21.12.2018
FormerThe international publication has been made
Status updated on  22.09.2017
Formerunknown
Status updated on  01.04.2017
Most recent event   Tooltip13.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 16.10.2024  [2024/42]
Applicant(s)For all designated states
Wisconsin Alumni Research Foundation
614 Walnut Street
Madison, WI 53726 / US
[2020/33]
Former [2019/04]For all designated states
Wisconsin Alumni Research Foundation
614 Walnut Street
Madison, WI 53705 / US
Inventor(s)01 / KWON, Glen S.
2 Hartleigh Court
Madison, WI 53705 / US
02 / TAM, Yu Tong
777 Highland Avenue
Madison, WI 53705 / US
 [2019/04]
Representative(s)Harrison IP Limited
3 Ebor House
Millfield Lane
Nether Poppleton
York YO26 6QY / GB
[N/P]
Former [2019/04]Harrison IP Limited
3 Ebor House
Millfield Lane
Nether Poppleton, York YO26 6QY / GB
Application number, filing date17712842.813.03.2017
[2019/04]
WO2017IB51455
Priority number, dateUS201662307830P14.03.2016         Original published format: US 201662307830 P
[2019/04]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017158499
Date:21.09.2017
Language:EN
[2017/38]
Type: A1 Application with search report 
No.:EP3429628
Date:23.01.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 21.09.2017 takes the place of the publication of the European patent application.
[2019/04]
Type: B1 Patent specification 
No.:EP3429628
Date:22.04.2020
Language:EN
[2020/17]
Search report(s)International search report - published on:EP21.09.2017
ClassificationIPC:A61K47/59, A61P35/00, A61K47/69
[2019/47]
CPC:
A61K47/593 (EP,KR,US); A61K31/337 (EP,KR,US); A61K31/4184 (EP,KR,US);
A61K31/436 (KR); A61K31/445 (EP,US); A61K31/517 (EP,US);
A61K47/542 (KR); A61K47/6907 (EP,KR,US); A61K9/0019 (KR,US);
A61P35/00 (EP,KR,US) (-)
Former IPC [2019/04]A61K47/59
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/04]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:OLIGOLMILCHSÄUREKONJUGATE UND MIZELLEN MIT VERBESSERTER KREBSBEKÄMPFENDER WIRKUNG[2019/04]
English:OLIGOLACTIC ACID CONJUGATES AND MICELLES WITH ENHANCED ANTICANCER EFFICACY[2019/04]
French:CONJUGUÉS D'ACIDE OLIGOLACTIQUE ET MICELLES PRÉSENTANT UNE EFFICACITÉ ANTICANCÉREUSE AMÉLIORÉE[2019/04]
Entry into regional phase27.09.2018National basic fee paid 
27.09.2018Designation fee(s) paid 
27.09.2018Examination fee paid 
Examination procedure27.09.2018Examination requested  [2019/04]
27.09.2018Date on which the examining division has become responsible
24.01.2019Amendment by applicant (claims and/or description)
31.10.2019Communication of intention to grant the patent
28.02.2020Fee for grant paid
28.02.2020Fee for publishing/printing paid
28.02.2020Receipt of the translation of the claim(s)
Divisional application(s)EP20165386.2  / EP3695851
Opposition(s)25.01.2021No opposition filed within time limit [2021/13]
Fees paidRenewal fee
13.03.2019Renewal fee patent year 03
12.03.2020Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU13.03.2017
AL22.04.2020
AT22.04.2020
CY22.04.2020
CZ22.04.2020
DK22.04.2020
EE22.04.2020
FI22.04.2020
HR22.04.2020
LT22.04.2020
LV22.04.2020
MC22.04.2020
MK22.04.2020
MT22.04.2020
NL22.04.2020
PL22.04.2020
RO22.04.2020
RS22.04.2020
SE22.04.2020
SI22.04.2020
SK22.04.2020
SM22.04.2020
TR22.04.2020
BG22.07.2020
NO22.07.2020
GR23.07.2020
IS22.08.2020
PT24.08.2020
[2024/42]
Former [2024/29]HU13.03.2017
AL22.04.2020
AT22.04.2020
CY22.04.2020
CZ22.04.2020
DK22.04.2020
EE22.04.2020
FI22.04.2020
HR22.04.2020
LT22.04.2020
LV22.04.2020
MC22.04.2020
MK22.04.2020
NL22.04.2020
PL22.04.2020
RO22.04.2020
RS22.04.2020
SE22.04.2020
SI22.04.2020
SK22.04.2020
SM22.04.2020
TR22.04.2020
BG22.07.2020
NO22.07.2020
GR23.07.2020
IS22.08.2020
PT24.08.2020
Former [2024/22]HU13.03.2017
AL22.04.2020
AT22.04.2020
CY22.04.2020
CZ22.04.2020
DK22.04.2020
EE22.04.2020
FI22.04.2020
HR22.04.2020
LT22.04.2020
LV22.04.2020
MC22.04.2020
MK22.04.2020
NL22.04.2020
PL22.04.2020
RO22.04.2020
RS22.04.2020
SE22.04.2020
SI22.04.2020
SK22.04.2020
SM22.04.2020
BG22.07.2020
NO22.07.2020
GR23.07.2020
IS22.08.2020
PT24.08.2020
Former [2023/33]HU13.03.2017
AL22.04.2020
AT22.04.2020
CY22.04.2020
CZ22.04.2020
DK22.04.2020
EE22.04.2020
FI22.04.2020
HR22.04.2020
LT22.04.2020
LV22.04.2020
MC22.04.2020
NL22.04.2020
PL22.04.2020
RO22.04.2020
RS22.04.2020
SE22.04.2020
SI22.04.2020
SK22.04.2020
SM22.04.2020
BG22.07.2020
NO22.07.2020
GR23.07.2020
IS22.08.2020
PT24.08.2020
Former [2023/30]AL22.04.2020
AT22.04.2020
CY22.04.2020
CZ22.04.2020
DK22.04.2020
EE22.04.2020
FI22.04.2020
HR22.04.2020
LT22.04.2020
LV22.04.2020
MC22.04.2020
NL22.04.2020
PL22.04.2020
RO22.04.2020
RS22.04.2020
SE22.04.2020
SI22.04.2020
SK22.04.2020
SM22.04.2020
BG22.07.2020
NO22.07.2020
GR23.07.2020
IS22.08.2020
PT24.08.2020
Former [2021/45]AL22.04.2020
AT22.04.2020
CZ22.04.2020
DK22.04.2020
EE22.04.2020
FI22.04.2020
HR22.04.2020
LT22.04.2020
LV22.04.2020
MC22.04.2020
NL22.04.2020
PL22.04.2020
RO22.04.2020
RS22.04.2020
SE22.04.2020
SI22.04.2020
SK22.04.2020
SM22.04.2020
BG22.07.2020
NO22.07.2020
GR23.07.2020
IS22.08.2020
PT24.08.2020
Former [2021/24]AL22.04.2020
AT22.04.2020
CZ22.04.2020
DK22.04.2020
EE22.04.2020
FI22.04.2020
HR22.04.2020
LT22.04.2020
LV22.04.2020
NL22.04.2020
PL22.04.2020
RO22.04.2020
RS22.04.2020
SE22.04.2020
SI22.04.2020
SK22.04.2020
SM22.04.2020
BG22.07.2020
NO22.07.2020
GR23.07.2020
IS22.08.2020
PT24.08.2020
Former [2021/10]AL22.04.2020
AT22.04.2020
CZ22.04.2020
DK22.04.2020
EE22.04.2020
FI22.04.2020
HR22.04.2020
LT22.04.2020
LV22.04.2020
NL22.04.2020
PL22.04.2020
RO22.04.2020
RS22.04.2020
SE22.04.2020
SK22.04.2020
SM22.04.2020
BG22.07.2020
NO22.07.2020
GR23.07.2020
IS22.08.2020
PT24.08.2020
Former [2021/09]AL22.04.2020
AT22.04.2020
CZ22.04.2020
DK22.04.2020
EE22.04.2020
FI22.04.2020
HR22.04.2020
LT22.04.2020
LV22.04.2020
NL22.04.2020
RO22.04.2020
RS22.04.2020
SE22.04.2020
SM22.04.2020
BG22.07.2020
NO22.07.2020
GR23.07.2020
IS22.08.2020
PT24.08.2020
Former [2021/08]AL22.04.2020
DK22.04.2020
FI22.04.2020
HR22.04.2020
LT22.04.2020
LV22.04.2020
NL22.04.2020
RO22.04.2020
RS22.04.2020
SE22.04.2020
SM22.04.2020
BG22.07.2020
NO22.07.2020
GR23.07.2020
IS22.08.2020
PT24.08.2020
Former [2021/04]AL22.04.2020
FI22.04.2020
HR22.04.2020
LT22.04.2020
LV22.04.2020
NL22.04.2020
RS22.04.2020
SE22.04.2020
BG22.07.2020
NO22.07.2020
GR23.07.2020
IS22.08.2020
PT24.08.2020
Former [2021/01]FI22.04.2020
HR22.04.2020
LT22.04.2020
LV22.04.2020
NL22.04.2020
RS22.04.2020
SE22.04.2020
BG22.07.2020
NO22.07.2020
GR23.07.2020
IS22.08.2020
PT24.08.2020
Former [2020/51]FI22.04.2020
HR22.04.2020
LT22.04.2020
LV22.04.2020
NL22.04.2020
RS22.04.2020
SE22.04.2020
NO22.07.2020
GR23.07.2020
IS22.08.2020
PT24.08.2020
Former [2020/50]FI22.04.2020
HR22.04.2020
LT22.04.2020
LV22.04.2020
NL22.04.2020
SE22.04.2020
NO22.07.2020
GR23.07.2020
IS22.08.2020
PT24.08.2020
Former [2020/48]FI22.04.2020
LT22.04.2020
NL22.04.2020
SE22.04.2020
NO22.07.2020
IS22.08.2020
PT24.08.2020
Former [2020/47]LT22.04.2020
NO22.07.2020
IS22.08.2020
Former [2020/46]IS22.08.2020
Cited inInternational search[A] US2011143993  (LANGER ROBERT S et al.)
 [A] US2011076308  (KWON GLEN S et al.)
by applicantUS4745160
 US6322805
   FARINA, V.: "The chemistry and pharmacology of Taxol and its derivatives", 1995, ELSEVIER
   WANDER, S. ET AL.: "Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy", J. CLIN. INVEST., vol. 121, no. 4, 2011, pages 1231 - 1241, XP055282986, DOI: doi:10.1172/JCI44145

DOI:   http://dx.doi.org/10.1172/JCI44145
   JOKINEN, E. ET AL.: "MEK and PI3K inhibition in solid tumors: rationale and evidence to date", THER. ADV. MED. ONCOL., vol. 7, no. 3, 2015, pages 170 - 180
   GAUCHER ET AL., J. CONTROLLED RELEASE, vol. 109, 2005, pages 169 - 188
   YASUGI ET AL., J CONTROL. RELEASE, vol. 62, 1999, pages 99 - 100
   "Remingtons Pharmaceutical Sciences", 1991, MACK PUB. CO.
   TAKIZAWA, K. ET AL., J. POLYM. SCI. A POLYM. CHEM., vol. 46, 2008, pages 5977 - 5990
   FORREST, M. L. ET AL., PHARM. RES.,, vol. 25, 2008, pages 194 - 206
   ALI, S. ET AL., ANTI-CANCER DRUGS, vol. 12, 2001, pages 117 - 128
   MAGRI, N. F. ET AL., J. ORG. CHEM., vol. 51, 1986, pages 3239 - 3242
   SHIN, H. ET AL., MOL. PHARM., vol. 8, 2011, pages 1257 - 1265
   CABRAL, H. ET AL., NAT. NANOTECHNOL., vol. 6, 2011, pages 815 - 823
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.